Why S.F. biotechs clinical trial may add to new dash for fatty liver disease NASH
ETNB Stock | USD 8.99 0.15 1.64% |
About 57% of 89bio's investor base is looking to short. The analysis of the overall investor sentiment regarding 89bio Inc suggests that many traders are alarmed. The current market sentiment, together with 89bio's historical and current headlines, can help investors time the market. In addition, many technical investors use 89bio Inc stock news signals to limit their universe of possible portfolio assets.
89bio |
Rohan Palekar is the CEO of 89bio.
Read at bizjournals.com
89bio Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards 89bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
89bio Fundamental Analysis
We analyze 89bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 89bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 89bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
89bio is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
89bio Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 89bio stock to make a market-neutral strategy. Peer analysis of 89bio could also be used in its relative valuation, which is a method of valuing 89bio by comparing valuation metrics with similar companies.
Peers
89bio Related Equities
XFOR | X4 Pharmaceuticals | 11.43 | ||||
HEPA | Hepion Pharmaceuticals | 4.69 | ||||
PLRX | Pliant Therapeutics | 2.00 | ||||
STOK | Stoke Therapeutics | 1.68 | ||||
HOOK | Hookipa Pharma | 1.61 | ||||
DAWN | Day One | 1.53 | ||||
MREO | Mereo BioPharma | 1.40 | ||||
ABOS | Acumen Pharmaceuticals | 0.44 | ||||
AKRO | Akero Therapeutics | 0.22 | ||||
INZY | Inozyme Pharma | 0.37 | ||||
TGTX | TG Therapeutics | 0.57 | ||||
MDGL | Madrigal Pharmaceuticals | 0.98 | ||||
ACLX | Arcellx | 1.12 | ||||
TERN | Terns Pharmaceuticals | 1.58 | ||||
VKTX | Viking Therapeutics | 2.88 |
Complementary Tools for 89bio Stock analysis
When running 89bio's price analysis, check to measure 89bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 89bio is operating at the current time. Most of 89bio's value examination focuses on studying past and present price action to predict the probability of 89bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 89bio's price. Additionally, you may evaluate how the addition of 89bio to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |